As pharmaceutical innovation advances into increasingly complex therapeutic and biomedical applications, excipient technologies are playing a more critical role than ever. At CPHI 2026 in Milan, GELITA will demonstrate how specialized gelatin and collagen-based excipients can help pharmaceutical and nutraceutical manufacturers overcome formulation challenges, improve product performance, and unlock new opportunities in drug delivery, nutrients supply and bioscience. The company will showcase its latest developments at booth 16H65 during the exhibition, taking place October 6–8 at Fiera Milano.
Recognized globally for its expertise in collagen proteins and pharmaceutical excipients, GELITA has built a strong reputation as a trusted innovation partner to the pharmaceutical and nutraceutical industry. With decades of experience in softgel technologies, the company continues to develop solutions that address key industry demands, ranging from improved formulation flexibility to enhanced stability and functionality of active ingredients.
A major focus at this year’s event will be GELITA’s advanced Softgel Specialty Portfolio. Designed specifically to tackle some of the most persistent challenges in soft capsule development, the portfolio includes technologies that support rapid fill release, enable true enteric softgel capsules, reduce leakage risks, and minimize crosslinking effects. These capabilities allow pharmaceutical developers greater freedom when designing formulations while helping ensure consistent product performance throughout shelf life. Such innovations are becoming increasingly important as manufacturers seek more sophisticated delivery systems for sensitive and complex active ingredients.
Beyond softgels, GELITA will also highlight its growing range of Endotoxin Controlled Excipients for bioscience applications. Developed to meet the stringent requirements of emerging biomedical fields, these excipients are designed for applications including vaccine stabilization, regenerative medicine, 3D bioprinting, and medical device technologies. Through rigorous endotoxin control, they help support the safety, reliability, and performance standards required in highly specialized pharmaceutical and biomedical environments. As innovation continues to blur the boundaries between pharmaceuticals, biologics, and advanced medical technologies, demand for such high-purity excipients is expected to grow significantly.
Visitors to the GELITA booth will also have the opportunity to engage directly with experts from the GELITA Pharma Institute. Through one-on-one discussions, attendees can explore specific development challenges, gain insights into formulation optimization, and learn how specialized excipient solutions can be adapted to their individual projects. These consultations provide valuable opportunities for pharmaceutical developers, R&D specialists, and product innovators seeking practical solutions to complex formulation requirements.
As the pharmaceutical industry continues to pursue novel drug delivery systems and breakthrough biomedical technologies, excipients are increasingly recognized as strategic enablers of innovation. At CPHI 2026, GELITA aims to demonstrate how its expertise in softgel technologies and bioscience excipients can help manufacturers transform scientific ideas into successful products. For visitors looking to stay ahead of emerging formulation trends, booth 16H65 will offer a glimpse into the future of pharmaceutical development.
